Research Study
View Full Study →
Preclinical Pharmacology of CX1837, a High-Impact Ampakine with an Improved Safety Margin: Implications for Treating Alzheimer's Disease and Ischemic Stroke.
Citation
Radin D., Zhong S., Cerne R., Shoaib M., Smith J. et al. (2025). Preclinical Pharmacology of CX1837, a High-Impact Ampakine with an Improved Safety Margin: Implications for Treating Alzheimer's Disease and Ischemic Stroke.. Curr Alzheimer Res. DOI: 10.2174/0115672050365821250127055828
Abstract
Abstract not available. See citation for source.
Disclaimer: This research summary is for educational purposes only. Always consult with a healthcare professional before making decisions based on scientific research.